Table 2.
Summary of inclusion body myositis therapeutic trials
| Targeting inflammatory pathways | Targeting degenerative pathways | Nonpharmacological therapeutic options | |
|---|---|---|---|
| Treatment agent | • Corticosteroids | • Arimoclomol | • Exercise |
| • Intravenous immunoglobulins | • Rapamycin | • Cricopharyngeal myotomy | |
| • Bimagrumab* | • Pharyngoesophageal dilation | ||
| • Methotrexate | • Follistatin* | ||
| • Azathioprine | • Oxandrolone* | ||
| • β-Interferon-1a | |||
| • Anti-T-lymphocyte globulin | |||
| • Etanercept | |||
| • Alemtuzumab | |||
| • Anakinra | |||
| • Simvastatin |
*Increases muscle mass